• eIF4E/XPO1 collaboratively transport GATA-3 and GATA-3 targets and are thus therapeutic vulnerabilities in GATA-3–driven TCLs.

  • Impaired eIF4E/XPO1 nuclear export, by depleting LAM, also has a non–cell-autonomous mechanism of action in the TCLs.

Abstract

The transcription factor GATA-binding protein 3 (GATA-3) and the transcriptional program it regulates have emerged as oncogenic drivers across diverse T-cell lymphomas (TCLs), many of which are resistant to conventional chemotherapeutic agents and characterized by recurrent losses of key tumor suppressor genes, including TP53 and PTEN, both of which are clients of the nuclear export protein XPO1. Here, we demonstrated that XPO1 is highly expressed by malignant T cells expressing GATA-3 and by lymphoma-associated macrophages (LAMs) within their tumor microenvironment (TME). Using complementary genetically engineered mouse models, we demonstrated that TP53- and/or phosphate and tensin homolog (PTEN)-deficient TCLs, and LAMs within their TME, are sensitive to the selective exportin-1 (XPO1) antagonist selinexor. In an effort to identify TP53- and PTEN-independent mechanisms, we used complementary and orthogonal approaches to investigate the role of eIF4E and XPO1-dependent messenger RNA nuclear export in these TCLs. We identified a novel role for eIF4E/XPO1 in exporting GATA-3 and GATA-3–dependent transcripts from the nucleus in TCLs, and in the export of therapeutically relevant transcripts, including colony-stimulating factor-1 receptor, from LAMs. Therefore, XPO1 antagonism, by impairing oncogenic transcriptional programs in TCLs and depleting LAMs from their TME, is a novel approach to target 2 independent dependencies in a group of therapeutically challenging TCLs.

1.
Mak
V
,
Hamm
J
,
Chhanabhai
M
, et al
.
Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors
.
J Clin Oncol
.
2013
;
31
(
16
):
1970
-
1976
.
2.
Zhang
JY
,
Briski
R
,
Devata
S
, et al
.
Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL)
.
Am J Hematol
.
2018
;
93
(
3
):
394
-
400
.
3.
Iqbal
J
,
Wright
G
,
Wang
C
, et al
.
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
.
Blood
.
2014
;
123
(
19
):
2915
-
2923
.
4.
Wang
T
,
Feldman
AL
,
Wada
DA
, et al
.
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
.
Blood
.
2014
;
123
(
19
):
3007
-
3015
.
5.
Wang
T
,
Lu
Y
,
Polk
A
, et al
.
T-cell receptor signaling activates an ITK/NF-kappaB/GATA-3 axis in T-cell lymphomas facilitating resistance to chemotherapy
.
Clin Cancer Res
.
2017
;
23
(
10
):
2506
-
2515
.
6.
Heavican
TB
,
Bouska
A
,
Yu
J
, et al
.
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
.
Blood
.
2019
;
133
(
15
):
1664
-
1676
.
7.
Geng
X
,
Wang
C
,
Gao
X
, et al
.
GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
.
Blood Cancer J
.
2022
;
12
(
11
):
149
.
8.
Hosoya
T
,
Maillard
I
,
Engel
JD
.
From the cradle to the grave: activities of GATA-3 throughout T-cell development and differentiation
.
Immunol Rev
.
2010
;
238
(
1
):
110
-
125
.
9.
Tindemans
I
,
Serafini
N
,
Di Santo
JP
,
Hendriks
RW
.
GATA-3 function in innate and adaptive immunity
.
Immunity
.
2014
;
41
(
2
):
191
-
206
.
10.
Pelletier
J
,
Graff
J
,
Ruggero
D
,
Sonenberg
N
.
Targeting the eIF4F translation initiation complex: a critical nexus for cancer development
.
Cancer Res
.
2015
;
75
(
2
):
250
-
263
.
11.
Pisera
A
,
Campo
A
,
Campo
S
.
Structure and functions of the translation initiation factor eIF4E and its role in cancer development and treatment
.
J Genet Genomics
.
2018
;
45
(
1
):
13
-
24
.
12.
Siddiqui
N
,
Sonenberg
N
.
Signalling to eIF4E in cancer
.
Biochem Soc Trans
.
2015
;
43
(
5
):
763
-
772
.
13.
Witzig
TE
,
Reeder
C
,
Han
JJ
, et al
.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
.
Blood
.
2015
;
126
(
3
):
328
-
335
.
14.
Cai
Q
,
Deng
H
,
Xie
D
,
Lin
T
,
Lin
T
.
Phosphorylated AKT protein is overexpressed in human peripheral T-cell lymphomas and predicts decreased patient survival
.
Clin Lymphoma Myeloma Leuk
.
2012
;
12
(
2
):
106
-
112
.
15.
Culjkovic-Kraljacic
B
,
Baguet
A
,
Volpon
L
,
Amri
A
,
Borden
KL
.
The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation
.
Cell Rep
.
2012
;
2
(
2
):
207
-
215
.
16.
Volpon
L
,
Culjkovic-Kraljacic
B
,
Sohn
HS
,
Blanchet-Cohen
A
,
Osborne
MJ
,
Borden
KLB
.
A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery
.
RNA
.
2017
;
23
(
6
):
927
-
937
.
17.
Azmi
AS
,
Uddin
MH
,
Mohammad
RM
.
The nuclear export protein XPO1–from biology to targeted therapy
.
Nat Rev Clin Oncol
.
2021
;
18
(
3
):
152
-
169
.
18.
Topisirovic
I
,
Siddiqui
N
,
Borden
KL
.
The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes
.
Cell Cycle
.
2009
;
8
(
7
):
960
-
961
.
19.
Topisirovic
I
,
Siddiqui
N
,
Lapointe
VL
, et al
.
Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP
.
EMBO J
.
2009
;
28
(
8
):
1087
-
1098
.
20.
Culjkovic
B
,
Topisirovic
I
,
Skrabanek
L
,
Ruiz-Gutierrez
M
,
Borden
KL
.
eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR
.
J Cell Biol
.
2005
;
169
(
2
):
245
-
256
.
21.
Culjkovic
B
,
Topisirovic
I
,
Skrabanek
L
,
Ruiz-Gutierrez
M
,
Borden
KL
.
eIF4E is a central node of an RNA regulon that governs cellular proliferation
.
J Cell Biol
.
2006
;
175
(
3
):
415
-
426
.
22.
Culjkovic
B
,
Tan
K
,
Orolicki
S
,
Amri
A
,
Meloche
S
,
Borden
KL
.
The eIF4E RNA regulon promotes the Akt signaling pathway
.
J Cell Biol
.
2008
;
181
(
1
):
51
-
63
.
23.
Gao
X
,
Kady
N
,
Wang
C
, et al
.
Targeting lymphoma-associated macrophage expansion via CSF1R/JAK inhibition is a therapeutic vulnerability in peripheral T-cell lymphomas
.
Cancer Res Commun
.
2022
;
2
(
12
):
1727
-
1737
.
24.
Beyersdorf
N
,
Werner
S
,
Wolf
N
,
Herrmann
T
,
Kerkau
T
.
Characterization of a new mouse model for peripheral T cell lymphoma in humans
.
PLoS One
.
2011
;
6
(
12
):
e28546
.
25.
Ayrault
O
,
Andrique
L
,
Seite
P
.
Involvement of the transcriptional factor E2F1 in the regulation of the rRNA promoter
.
Exp Cell Res
.
2006
;
312
(
7
):
1185
-
1193
.
26.
Burger
K
,
Muhl
B
,
Rohrmoser
M
, et al
.
Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA
.
J Biol Chem
.
2013
;
288
(
29
):
21173
-
21183
.
27.
Lopez
DJ
,
Rodriguez
JA
,
Banuelos
S
.
Nucleophosmin, a multifunctional nucleolar organizer with a role in DNA repair
.
Biochim Biophys Acta Proteins Proteom
.
2020
;
1868
(
12
):
140532
.
28.
Okuwaki
M
,
Saito
S
,
Hirawake-Mogi
H
,
Nagata
K
.
The interaction between nucleophosmin/NPM1 and the large ribosomal subunit precursors contribute to maintaining the nucleolar structure
.
Biochim Biophys Acta Mol Cell Res
.
2021
;
1868
(
1
):
118879
.
29.
Pelletier
J
,
Thomas
G
,
Volarevic
S
.
Ribosome biogenesis in cancer: new players and therapeutic avenues
.
Nat Rev Cancer
.
2018
;
18
(
1
):
51
-
63
.
30.
Barna
M
,
Pusic
A
,
Zollo
O
, et al
.
Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency
.
Nature
.
2008
;
456
(
7224
):
971
-
975
.
31.
Song
X
,
Chang
S
,
Seminario-Vidal
L
, et al
.
Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma
.
Cancer Discov
.
2022
;
12
(
5
):
1294
-
1313
.
32.
Wilcox
RA
.
A three-signal model of T-cell lymphoma pathogenesis
.
Am J Hematol
.
2016
;
91
(
1
):
113
-
122
.
33.
Wilcox
RA
,
Wada
DA
,
Ziesmer
SC
, et al
.
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
.
Blood
.
2009
;
114
(
14
):
2936
-
2944
.
34.
Huang
SC
,
Smith
AM
,
Everts
B
, et al
.
Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation
.
Immunity
.
2016
;
45
(
4
):
817
-
830
.
35.
Murga-Zamalloa
C
,
Rolland
DCM
,
Polk
A
, et al
.
Colony-stimulating factor 1 receptor (CSF1R) activates AKT/mTOR signaling and promotes T-cell lymphoma viability
.
Clin Cancer Res
.
2020
;
26
(
3
):
690
-
703
.
36.
Dai
XM
,
Ryan
GR
,
Hapel
AJ
, et al
.
Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects
.
Blood
.
2002
;
99
(
1
):
111
-
120
.
37.
Wiktor-Jedrzejczak
W
,
Bartocci
A
,
Ferrante
AW
, et al
.
Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse
.
Proc Natl Acad Sci U S A
.
1990
;
87
(
12
):
4828
-
4832
.
38.
Celada
A
,
Borras
FE
,
Soler
C
, et al
.
The transcription factor PU.1 is involved in macrophage proliferation
.
J Exp Med
.
1996
;
184
(
1
):
61
-
69
.
39.
Klemsz
MJ
,
McKercher
SR
,
Celada
A
,
Van Beveren
C
,
Maki
RA
.
Pillars article: the macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell, 1990. 61: 113-124
.
J Immunol
.
2008
;
181
(
3
):
1597
-
1608
.
40.
Lloberas
J
,
Soler
C
,
Celada
A
.
The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages
.
Immunol Today
.
1999
;
20
(
4
):
184
-
189
.
41.
Liu
Z
,
Gu
Y
,
Chakarov
S
, et al
.
Fate mapping via Ms4a3-expression history traces monocyte-derived cells
.
Cell
.
2019
;
178
(
6
):
1509
-
1525.e19
.
42.
Kalakonda
N
,
Maerevoet
M
,
Cavallo
F
, et al
.
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
.
Lancet Haematol
.
2020
;
7
(
7
):
e511
-
e522
.
43.
Kuruvilla
J
,
Savona
M
,
Baz
R
, et al
.
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
.
Blood
.
2017
;
129
(
24
):
3175
-
3183
.
44.
Choi
J
,
Goh
G
,
Walradt
T
, et al
.
Genomic landscape of cutaneous T cell lymphoma
.
Nat Genet
.
2015
;
47
(
9
):
1011
-
1019
.
45.
da Silva Almeida
AC
,
Abate
F
,
Khiabanian
H
, et al
.
The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome
.
Nat Genet
.
2015
;
47
(
12
):
1465
-
1470
.
46.
Lamprecht
B
,
Kreher
S
,
Mobs
M
, et al
.
The tumour suppressor p53 is frequently nonfunctional in Sezary syndrome
.
Br J Dermatol
.
2012
;
167
(
2
):
240
-
246
.
47.
Golomb
L
,
Bublik
DR
,
Wilder
S
, et al
.
Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis
.
Mol Cell
.
2012
;
45
(
2
):
222
-
232
.
48.
Moy
TI
,
Silver
PA
.
Nuclear export of the small ribosomal subunit requires the ran-GTPase cycle and certain nucleoporins
.
Genes Dev
.
1999
;
13
(
16
):
2118
-
2133
.
49.
Rouquette
J
,
Choesmel
V
,
Gleizes
PE
.
Nuclear export and cytoplasmic processing of precursors to the 40S ribosomal subunits in mammalian cells
.
EMBO J
.
2005
;
24
(
16
):
2862
-
2872
.
50.
Zemp
I
,
Kutay
U
.
Nuclear export and cytoplasmic maturation of ribosomal subunits
.
FEBS Lett
.
2007
;
581
(
15
):
2783
-
2793
.
51.
Keene
JD
.
RNA regulons: coordination of post-transcriptional events
.
Nat Rev Genet
.
2007
;
8
(
7
):
533
-
543
.
52.
Culjkovic-Kraljacic
B
,
Fernando
TM
,
Marullo
R
, et al
.
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas
.
Blood
.
2016
;
127
(
7
):
858
-
868
.
53.
Marullo
R
,
Rutherford
SC
,
Revuelta
MV
, et al
.
XPO1 enables adaptive regulation of mRNA export required for genotoxic stress tolerance in cancer cells
.
Cancer Res
.
2024
;
84
(
1
):
101
-
117
.
54.
Watt
S
,
Vasquez
L
,
Walter
K
, et al
.
Genetic perturbation of PU.1 binding and chromatin looping at neutrophil enhancers associates with autoimmune disease
.
Nat Commun
.
2021
;
12
(
1
):
2298
.
55.
Seymour
EK
,
Khan
HY
,
Li
Y
, et al
.
Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: results of a phase I study
.
Clin Cancer Res
.
2021
;
27
(
12
):
3307
-
3316
.
56.
Tang
T
,
Martin
P
,
Somasundaram
N
, et al
.
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
.
Haematologica
.
2020
;
106
(
12
):
3170
-
3175
.
57.
Giliberto
M
,
Thimiri Govinda Raj
DB
,
Cremaschi
A
, et al
.
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
.
Mol Oncol
.
2022
;
16
(
6
):
1241
-
1258
.
58.
Geng
X
,
Wang
C
,
Abdelrahman
S
, et al
.
GATA-3 dependent gene transcription is impaired upon HDAC inhibition
.
Clin Cancer Res
.
2024
;
30
(
5
):
1054
-
1066
.
59.
Hing
ZA
,
Fung
HY
,
Ranganathan
P
, et al
.
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
.
Leukemia
.
2016
;
30
(
12
):
2364
-
2372
.
You do not currently have access to this content.
Sign in via your Institution